SEC22B2P

Across TCGA pan-cancer cohorts, SEC22B2P RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of SEC22B2P’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where SEC22B2P RNA is repressed in tumor relative to normal tissue. In most cancer types SEC22B2P is over-expressed in tumor, although a few such as BRCA and LUAD show the opposite, repressed pattern.

BRCA, KICH, and LUAD are the cancer types where SEC22B2P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SEC22B2P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	III,IV	−0.068	.006	2	view →
KICH	Female	III,IV	+0.090	<.001	1	view →
LUAD	All	All	−0.031	.049	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

SEC22B2P–BRCA

Open the BRCA breakdown →